Literature DB >> 12913319

Tumour regression of uveal melanoma after ruthenium-106 brachytherapy or stereotactic radiotherapy with gamma knife or linear accelerator.

Michael Georgopoulos1, Martin Zehetmayer, Irene Ruhswurm, Sabine Toma-Bstaendig, Nikolaus Ségur-Eltz, Stefan Sacu, Rupert Menapace.   

Abstract

PURPOSE: This study assesses differences in relative tumour regression and internal acoustic reflectivity after 3 methods of radiotherapy for uveal melanoma: (1) brachytherapy with ruthenium-106 radioactive plaques (RU), (2) fractionated high-dose gamma knife stereotactic irradiation in 2-3 fractions (GK) or (3) fractionated linear-accelerator-based stereotactic teletherapy in 5 fractions (Linac).
METHODS: Ultrasound measurements of tumour thickness and internal reflectivity were performed with standardised A scan pre-operatively and 3, 6, 9, 12, 18, 24 and 36 months postoperatively. Of 211 patients included in the study, 111 had a complete 3-year follow-up (RU: 41, GK: 37, Linac: 33). Differences in tumour thickness and internal reflectivity were assessed with analysis of variance, and post hoc multiple comparisons were calculated with Tukey's honestly significant difference test.
RESULTS: Local tumour control was excellent with all 3 methods (>93%). At 36 months, relative tumour height reduction was 69, 50 and 30% after RU, GK and Linac, respectively. In all 3 treatment groups, internal reflectivity increased from about 30% initially to 60-70% 3 years after treatment.
CONCLUSION: Brachytherapy with ruthenium-106 plaques results in a faster tumour regression as compared to teletherapy with gamma knife or Linac. Internal reflectivity increases comparably in all 3 groups. Besides tumour growth arrest, increasing internal reflectivity is considered as an important factor indicating successful treatment. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12913319     DOI: 10.1159/000071345

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  6 in total

1.  Uveal Melanoma Regression after Brachytherapy: Relationship with Chromosome 3 Monosomy Status.

Authors:  Sachin M Salvi; Hassan A Aziz; Suhail Dar; Nakul Singh; Brandy Hayden-Loreck; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2016-10-29

2.  Initial results of fractionated CyberKnife radiosurgery for uveal melanoma.

Authors:  Faruk Zorlu; Ugur Selek; Hayyam Kiratli
Journal:  J Neurooncol       Date:  2009-02-22       Impact factor: 4.130

3.  Regression patterns of choroidal melanoma: After palladium-103 (103Pd) plaque brachytherapy.

Authors:  Abhilasha Maheshwari; Paul T Finger
Journal:  Eur J Ophthalmol       Date:  2018-05-22       Impact factor: 2.597

4.  Radiological and clinical findings in uveal melanoma treated by plaque interventional radiotherapy (brachytherapy): Visual atlas and literature review on response assessment.

Authors:  Bruno Fionda; Monica Maria Pagliara; Valentina Lancellotta; Carmela Grazia Caputo; Calogero Casà; Maria Grazia Sammarco; Elisa Placidi; Patrizia Cornacchione; Francesco Boselli; Roberto Iezzi; Cesare Colosimo; Luca Tagliaferri; Maria Antonietta Blasi
Journal:  J Contemp Brachytherapy       Date:  2022-02-04

Review 5.  Efficacy and complications of ruthenium-106 brachytherapy for uveal melanoma: a systematic review and meta-analysis.

Authors:  Saeed Karimi; Amir Arabi; Zahra Siavashpour; Toktam Shahraki; Iman Ansari
Journal:  J Contemp Brachytherapy       Date:  2021-05-18

6.  Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy.

Authors:  Gilda Cennamo; Daniela Montorio; Luca D' Andrea; Antonio Farella; Elide Matano; Mario Giuliano; Raffaele Liuzzi; Maria Angelica Breve; Sabino De Placido; Giovanni Cennamo
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.